ストックスクリーナーアプリを入手
433.68
2.17%
8.82
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Madrigal Pharmaceuticals stock hits all-time high at 423.4 USD By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN
Is a relief rally coming for Madrigal Pharmaceuticals Inc. holders2025 Institutional Moves & Detailed Earnings Play Strategies - Newser
Should you wait for a breakout in Madrigal Pharmaceuticals Inc.July 2025 Final Week & High Accuracy Trade Signal Alerts - Newser
Is Madrigal Pharmaceuticals Inc. forming a bottoming base2025 Market Overview & Technical Confirmation Alerts - Newser
Madrigral Pharmaceuticals gains amid takeover speculation - MSN
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Benzinga
Is Madrigal Pharmaceuticals Inc. still worth holding after the dipMarket Movement Recap & Safe Entry Momentum Tips - Newser
How to forecast Madrigal Pharmaceuticals Inc. trends using time seriesInflation Watch & Fast Exit and Entry Strategy Plans - Newser
Is Madrigal Pharmaceuticals Inc. building a consolidation basePortfolio Profit Report & Precise Trade Entry Recommendations - Newser
Backtesting results for Madrigal Pharmaceuticals Inc. trading strategiesJuly 2025 Market Mood & Verified Technical Trade Signals - Newser
How to track smart money flows in Madrigal Pharmaceuticals Inc.Inflation Watch & Real-Time Price Movement Reports - Newser
Madrigal Pharmaceuticals price target raised to $485 from $483 at Citizens JMP - MSN
What to do if you’re stuck in Madrigal Pharmaceuticals Inc.Weekly Trend Report & AI Forecasted Stock Moves - Newser
Will Madrigal Pharmaceuticals Inc. stock go up soonJuly 2025 Breakouts & Real-Time Market Trend Scan - Newser
Momentum Indicator Shows Bearish Divergence in Madrigal Pharmaceuticals Inc.Earnings Miss & Weekly Setup with High ROI Potential - beatles.ru
Real time social sentiment graph for Madrigal Pharmaceuticals Inc.2025 Price Momentum & Short-Term Swing Trade Alerts - Newser
What momentum shifts mean for Madrigal Pharmaceuticals Inc.Weekly Trend Report & Proven Capital Preservation Tips - Newser
Madrigal Pharmaceuticals Grants Equity Awards to New Employees - MSN
Madrigal Pharmaceuticals Secures EU Approval for First-Ever MASH Therapy - MSN
Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)? - Yahoo Finance
Identifying reversal signals in Madrigal Pharmaceuticals Inc.Inflation Watch & Reliable Intraday Trade Plans - Newser
Technical signs of recovery in Madrigal Pharmaceuticals Inc.Quarterly Profit Review & Technical Pattern Based Signals - Newser
How moving averages guide Madrigal Pharmaceuticals Inc. trading2025 Buyback Activity & Fast Gain Stock Trading Tips - Newser
Will Madrigal Pharmaceuticals Inc. see short term momentumJuly 2025 Trade Ideas & Community Verified Trade Alerts - Newser
What to expect from Madrigal Pharmaceuticals Inc. in the next 30 daysBuy Signal & Expert Approved Momentum Trade Ideas - Newser
What machine learning models say about Madrigal Pharmaceuticals Inc.2025 Pullback Review & Real-Time Stock Price Movement Reports - Newser
What is the target price for Madrigal Pharmaceuticals Inc. stockJuly 2025 Closing Moves & Fast Moving Stock Watchlists - theviewers.co.kr
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU - MSN
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues - simplywall.st
Madrigal Pharmaceuticals Surges 3.94% on $240M Volume Spike Climbs to 362nd in Market Trading Rank - AInvest
Madrigal Pharmaceuticals: Insider Selling Amid Institutional Optimism – A Signal or a Symptom? - AInvest
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq listing rule 5635(c)(4) - MarketScreener
Madrigal Pharmaceuticals Announces Grants of Inducement Awards u - GuruFocus
Madrigal Pharmaceuticals Grants Inducement Awards to New Employees under Nasdaq Listing Rule 5635(c)(4) - AInvest
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rezdiffra's EU Approval: A Strategic Inflection Point for Madrigal and the MASH Market - AInvest
Madrigal Regains Lead With Rezdiffra MASH Approval In EU - insights.citeline.com
Madrigal Pharmaceuticals Receives Conditional Marketing Authorization for Rezdiffra in Europe - AInvest
Madrigal Pharmaceuticals Inc. Rebound Backed by Sentiment ShiftWeekly Trade Analysis & Expert Curated Trade Setup Alerts - newsyoung.net
How hedge fund analytics apply to Madrigal Pharmaceuticals Inc. stockWeekly Stock Recap & Target Return Focused Picks - Newser
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
Madrigal gets EU nod for its MASH treatment (MDGL:NASDAQ) - Seeking Alpha
Madrigal wins EC approval for Rezdiffra in MASH - The Pharma Letter
How Resilient Is Madrigal Pharmaceuticals Inc. Stock During Economic DownturnsMarket Movement Recap & AI Forecasted Entry and Exit Points - Newser
Madrigal’s MASH treatment Rezdiffra receives EU approval By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN
Madrigal’s MASH treatment Rezdiffra receives EU approval - Investing.com
Madrigal Pharmaceuticals' Rezdiffra Becomes First Approved Treatment for MASH in the European Union - Quiver Quantitative
Madrigal Receives European Commission Approval for - GlobeNewswire
Madrigal Pharmaceuticals, Inc. Receives European Commission Approval for Rezdiffra for the Treatment of MASH with Moderate to Advanced Liver Fibrosis - MarketScreener
Insider Selling at Madrigal Pharmaceuticals: Signal or Noise in the NASH Therapeutics Sector? - AInvest
Madrigal Pharmaceuticals’ general counsel sells $479,626 in stock By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals’ general counsel sells $479,626 in stock - Investing.com
Madrigal Pharmaceuticals stock reaches all-time high at 378.0 USD - Investing.com
Madrigal Pharmaceuticals stock reaches all-time high at 378.0 USD By Investing.com - Investing.com UK
Madrigal Pharmaceuticals stock maintains Buy rating at Goldman Sachs amid Wegovy approval - Investing.com Canada
Madrigal Pharmaceuticals Faces Market Jitters Amid New Rival - TipRanks
Why Nova Nordisk (NVO) Stock Is Climbing Today - Yahoo Finance
Madrigal stock falls after Novo Nordisk’s Wegovy wins FDA approval for MASH - Investing.com Canada
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN
Madrigal Pharmaceuticals, Inc. (MDGL)’s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3 - MSN
Is Madrigal Pharmaceuticals Inc. stock a hidden gemMarket Growth Summary & Low Drawdown Trading Techniques - classian.co.kr
1.16%
7.60%
大文字化:
|
ボリューム (24 時間):